Skip directly to content

標靶治療 Targeted Therapy

Besponsa®

Besponsa® is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). 1

Reference:

1. Besponsa® (inotuzumab ozogamicin) Prescribing Information. Pfizer Corporation Hong Kong Limited Version (Nov 2018)

[PP-CPF-HKG-0070] SEP 2019

Ibrance®愛搏新®

Ibrance® is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer1. Ibrance® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.

References:

  1. Ibrance® (palbociclib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (January 2018)
  2. Items Supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at

Inlyta®

Inlyta® is a second line oral therapy that targets VEGF receptor-related renal cell abnormalities1. Inlyta® has been enlisted as subsidized medical treatment against one specific disease by the Community Care Fund2.

 

Reference:

  1. Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2014
  2. Safety Net. HA Drug Formulary Management.  Accessed on 8 August 2019. https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#

[PP-CPF-HKG-0070] SEP 2019

Xalkori®

Xalkori® is a FDA-approved targeted therapy targeting lung cells harboring ALK or ROS-1 mutation1. Xalkori® has been enlisted as subsidized medical treatment against one specific disease by the Samaritan Fund. 2

 

參考資料:

  1. Xalkori® (crizotinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (August 2018)
  2. Information for Samaritan Fund & Community Care Fund Medical Assistance Programmes – Application for Drug Items. Hong Kong Hospital Authority. Accessed on 17 June 2019. Available at http://www.ha.org.hk/haho/ho/sf/Capping_leaflet_en.pdf.

[PP-CPF-HKG-0070] SEP 2019

Sutent®

Sutent® proactively antagonizes the metastatic problems with proliferative renal cell, gastrointestinal stromal cell and pancreatic neuroendocrine cell.1 Approved by FDA and with recommendation by NICE(UK) guideline2, Sutent® has been enlisted as subsidized medical treatment against two specific diseases by the Community Care Fund.3

Reference:

  1. Sutent® (sunitinib malate) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version May 2015.
  2. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 169. March 2009.
  3. Items supported by the Samaritan Fund